Tech Company Financing Transactions
Ousia Pharma Funding Round
On 5/6/2025, Ousia Pharma announced Seed funding from Omega Funds.
Transaction Overview
Company Name
Announced On
5/6/2025
Transaction Type
Venture Equity
Amount
Unknown
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to support the preclinical and clinical development of its once-weekly, dual-incretin-NMDA receptor antagonist conjugate.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Ole Maaløes Vej 3
Copenhagen N, 2200
Denmark
Copenhagen N, 2200
Denmark
Phone
Undisclosed
Website
Email Address
Overview
Ousia Pharma ApS is a Danish biotech start-up focused on the development of novel peptide-drug conjugates for the treatment of metabolic diseases. We utilize a targeting approach in which peptides are used to deliver modulators of synaptic plasticity to appetite controlling regions of the brain. We are pioneering innovative therapeutic strategies centered on peptide-drug conjugates to improve the lives of patients with cardiometabolic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Ian Laquian
Chief Executive Officer
Anders Klein
Chief Operating Officer
Jonas Petersen
Chief Scientific Officer
Christoffer Clemmensen
Browse more venture capital transactions:
Prev: 5/6/2025: Siegel Family Endowment venture capital transaction
Next: 5/6/2025: Posha venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs